PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2011 | 6 | 1 | 98-102
Article title

The effects of one-year simvastatin therapy on women’s bone mineral density

Content
Title variants
Languages of publication
EN
Abstracts
EN
Only few studies have reported that bone fracture risk is decreased in hypercholesterolemic postmenopausal women treated with statin therapy. Because of a lack of longitudinal studies on the effect of statins on bones, the aim of our investigation was to estimate the simvastatin therapy effects on bone mineral density in hypercholesterolemic postmenopausal women. Our investigation was carried out on 53 postmenopausal women with hypercholesterolemia. The women included in the study were divided into two groups. Group 1 was comprised of women with two or more (n=32) atherosclerosis risk factors, whereas group 2 had women with less than two (n=21) of these risk factors. All the women included in the study were placed on a hypocholesterolemic diet and the women in group 1 were additionally treated with 20 mg of simvastatin daily. The parameters of lipid status, body mass index, and L2–L4 densitometry were determined at baseline and then after one year. The simvastatin-treated group showed significant improvement of lipid parameters and increased bone mineral density. Finally, changes in bone mineral density between the groups showed significant differences (p<0.05). Although our investigation was carried out on a small group, our results showed a positive effect of the simvastatin therapy on the bone mineral density of postmenopausal women.
Publisher
Journal
Year
Volume
6
Issue
1
Pages
98-102
Physical description
Dates
published
1 - 2 - 2011
online
16 - 12 - 2010
References
  • [1] La Rosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–2346 http://dx.doi.org/10.1001/jama.282.24.2340[Crossref]
  • [2] Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: A randomized placebo-controlled trial. Lancet 2002; 360: 7–22 http://dx.doi.org/10.1016/S0140-6736(02)09327-3[Crossref]
  • [3] van Beek E, Lowik C, van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999; 14: 722–729 http://dx.doi.org/10.1359/jbmr.1999.14.5.722[Crossref]
  • [4] Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000; 27: 585–590 http://dx.doi.org/10.1016/S8756-3282(00)00381-1[Crossref]
  • [5] Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946–1949 http://dx.doi.org/10.1126/science.286.5446.1946[Crossref]
  • [6] Reid IR, Tonkin A, Cannon CP. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial-Secondary analysis of a randomized controlled trial. Bone 2005; 37: 190–191 http://dx.doi.org/10.1016/j.bone.2005.04.012[Crossref]
  • [7] Wang PS, Solomon DH, Mogun H, Avorn J. HMGCoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283: 3211–3216 http://dx.doi.org/10.1001/jama.283.24.3211[Crossref]
  • [8] Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355: 2185–2188 http://dx.doi.org/10.1016/S0140-6736(00)02400-4[Crossref]
  • [9] Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2002; 162: 537–540 http://dx.doi.org/10.1001/archinte.162.5.537[Crossref]
  • [10] van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001; 285: 1850–1855 http://dx.doi.org/10.1001/jama.285.14.1850[Crossref]
  • [11] Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, et al. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischemic Disease. Lancet 2001; 357: 509–512 http://dx.doi.org/10.1016/S0140-6736(00)04042-3[Crossref]
  • [12] Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. 4S Study Group. JAMA 2000; 284: 1921–1922 http://dx.doi.org/10.1001/jama.284.15.1921[Crossref]
  • [13] Adami S, Braga V, Gatti D. Association between bone mineral density and serum lipids in men. JAMA 2001; 286: 791–792 http://dx.doi.org/10.1001/jama.286.7.791[Crossref]
  • [14] Chung YS, Lee MD, Lee SK, Kim HM, Fitzpartick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000; 85: 1137–1142 http://dx.doi.org/10.1210/jc.85.3.1137[Crossref]
  • [15] Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000; 355: 2218–2219 http://dx.doi.org/10.1016/S0140-6736(00)02408-9[Crossref]
  • [16] Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1-year treatment with Fluvastatin or Pravastatin on bone. Am J Med 2001; 110: 584–587 http://dx.doi.org/10.1016/S0002-9343(01)00679-9[Crossref]
  • [17] Montagnani A, Gonnelli S, Cepollaro C, Pacini S, Campagna MS, Franci MB. Effect of Simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: A 1-year longitudinal study. Bone 2003; 32: 427–433 http://dx.doi.org/10.1016/S8756-3282(03)00034-6[Crossref]
  • [18] Rejinmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L. Statins decrease bone turnover in postmenopausal women: A cross sectional study. Eur J Clin Invest 2002; 32: 581–589 http://dx.doi.org/10.1046/j.1365-2362.2002.01024.x[Crossref]
  • [19] Hatzigeorgiou CC., Jackson JL. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 2005; 16: 990–998 http://dx.doi.org/10.1007/s00198-004-1793-0[Crossref]
  • [20] Lane NE, Rehman Q. Osteoporosis in the rheumatic disease patient. Lupus 2002; 11: 675–679 http://dx.doi.org/10.1191/0961203302lu261oa[Crossref]
  • [21] Satyawan BJ, Girish KJ. Statins and osteoporosis. J Pharm Pharmacol 2006, 58: 3–18
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11536-010-0031-8
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.